Emerging Therapies and Future Directions in Metastatic CSPC | CME

13 Visioni

  • Grazie! Condividilo con i tuoi amici!

    Non hai gradito questo video. Grazie per il feedback!

admin
Published
Watch this segment to gain expert insights in metastatic CSPC, and then visit https://i3health.com/course-information/cspc-escape to explore the full escape room experience.

In this video, Dr. Ulka Vaishampayan, Professor of Medicine/Oncology and Co-Leader of the Translational Clinical Research Program at the University of Michigan Rogel Cancer Center @MichiganMedicine reviews trials that are poised to transform the standard of care in metastatic castration-sensitive prostate cancer (mCSPC). Dr. Vaishampayan covers:

- Frontline PARP inhibitor combinations in the AMPLITUDE trial
- PSMA-targeted radioligand therapy in the UpFrontPSMA and PSMAddition trials

About the series:
This clip is part of an immersive, case-based escape room designed to challenge participants through real-world scenarios.

Follow us here:
Facebook https://www.facebook.com/i3Health
Instagram https://www.instagram.com/i3health
Linkedin https://www.linkedin.com/company/i3health
Soundcloud https://soundcloud.com/i3-health
X https://twitter.com/i3health

#prostatecancer #cspc #oncology #metastaticprostatecancer #medicaleducation #News #education #cme #cancer #cancertreatment #earlydiagnosis #patientcare #cancercare #cancerpatient #cancerdetection #prostatecancerawareness #metastaticcancer #prostatehealth
Categoria
Oncology
Commenta per primo questo video.

Prossimo